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Abstract 
Objectives: To unravel the perspective of patients with early rheumatoid arthritis (ERA) on 
preferred health and treatment outcomes at two time points during the early stage of their 
disease and treatment. 
Methods: In a longitudinal, qualitative, explorative study, we individually interviewed 26 
patients with ERA 4-6 months after start of the initial rheumatoid arthritis (RA) treatment. 
Fourteen of these participants took part in 1 of 3 focus groups at least one year after 
treatment initiation. Interviews were audiotaped, transcribed verbatim and analyzed using the 
constant comparison method. Two patient researchers completed the interdisciplinary 
research team. 
Findings: Patients with ERA ultimately strive to be normal again, literally and figuratively. 
Outcome preferences inherent to this urge for normality were related to aspects of disease 
control, physical aspects, aspects of participation and mental aspects. Initially, patient 
outcome preferences in ERA were primarily related to pain relief, medication side effects and 
burden, and emotional well-being. Patient-preferred outcomes evolved over the ERA disease 
course, with subtle changes in terminology used by participants and with pain relief staying in 
the foreground.  
Conclusion: From a patient perspective, normality is the ultimate outcome to target in ERA. 
Our study produced knowledge for designing more targeted therapeutic interventions aimed 
at normalizing patients’ health and life in all its aspects during a crucial phase of RA. 
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Significance and Innovations 
• Striving for shared decision making between health-care professionals and patients at the 
earliest stage of care is imperative to achieve effective and efficient rheumatoid arthritis 
management. 
• Longitudinal qualitative research in patients with early rheumatoid arthritis reveals the 
dynamics in patients’ outcome preferences pointing to “normality” as a key target. 
• These findings should be applied in order to optimize care in a crucial disease phase, by 
enhancing early interventions, which in turn may prevent long-term disease 
consequences. 
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Introduction 
Despite effective pharmacological treatments available, patients with rheumatoid arthritis 
(RA) continue to report unmet needs, and the impact on the individual and society remains 
considerable (1, 2). This care gap suggests that patients’ health and treatment preferences 
are not sufficiently understood and met. Outcome assessment in RA has already changed 
profoundly in that the patient’s perspective and patient-reported outcomes (PROs) are now 
being considered. However, the question remains which outcomes to evaluate and how to 
measure them, with maybe different answers from the patients’ and health-care 
professionals’ perspective (3, 4). 
 
The importance of responding to patients’ needs and preferences cannot be overstated in 
chronic conditions (4, 5). Patient preferences are molded by their perspectives, beliefs, 
expectations, and goals for health and life (6). Health-care professionals and patients share 
common treatment goals. However, additionally targeting patient-preferred outcomes may 
improve patients’ treatment adherence and satisfaction, leading to better health outcomes 
(7). This patient-centered focus has been acknowledged as a priority health-care quality 
dimension (8). 
 
Not all PROs are patient-centered and conversely, often not all outcomes that truly matter to 
patients are measured (9). Qualitative studies on the patient perspective in RA have 
challenged outcomes and outcome core sets held by health-care professionals, discovering 
that patient preferences could go beyond the traditional RA measures of disease activity and 
severity (10-12). None of these cross-sectional qualitative studies focused on what matters 
specifically to patients with early RA (ERA), while outcome preferences can differ depending 
on disease duration (13). Such early changes in health perceptions and preferences find a 
conceptual basis in for example the chronic illness trajectory framework that describes, 
depending on the stage in an individual’s illness trajectory, dynamics in illness experiences, 
self-perceptions, expectations, and care needs (14). 
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Although there is no clear definition of ERA from the patient perspective in literature, the 
early disease stage is probably the most precarious period for patients, because in this stage 
they lack disease-related experience, knowledge, and awareness (15). Moreover, treating 
RA during its earliest stage likely increases chances for positive, long-term outcomes (16). 
 
Since perceptions and expectations of newly diagnosed patients may change during the 
overwhelming and rapidly evolving early disease stage, a longitudinal perspective would 
expand our understanding on outcome preferences in ERA. This study aims to prospectively 
unravel the perspective of patients with ERA on preferred health and treatment outcomes. 
 
 
Patients and Methods 
Study design 
We performed a longitudinal, qualitative, explorative study in collaboration with two patient 
research partners with RA (AG, EB) (17). Participants were invited to be interviewed twice 
over a one-year period in the ERA phase: once in an individual interview (t1) and once in 
focus groups (t2). 
 
We reasoned that conducting individual interviews at t1 was preferable, because sharing 
personal opinions in a group setting could be delicate for recently diagnosed patients, as 
confirmed by our patient researchers. These interviews were conducted 4-6 months after 
treatment initiation, which should be sufficient time for diagnostic procedures to be finalized 
and RA therapy to be ongoing. Furthermore, we assumed that after 4-6 months participants 
would be better able to grasp different disease and treatment aspects and communicate 
about their outcome preferences. At t2, focus groups were considered to be preferable, as 
group interactions encourage persons to share their thoughts and beliefs, which can result in 
more and varied data (18). Furthermore, focus groups provide views other than those 
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provided by individual interviews, which also possibly enriches the data (19, 20). Conducting 
the focus groups at least one year after treatment initiation helped participants to develop 
disease perspective and to feel more comfortable in sharing their story. Participants would by 
then probably have already informally interacted with peers. 
 
Context 
The present study was embedded in the Care for early RA (CareRA) trial; a prospective two-
year, investigator-initiated, multicenter, randomized controlled trial rooted in daily practice, 
which compares initial treatment combinations in ERA (21). Patients fulfilled the American 
College of Rheumatology 1987 classification criteria for RA (22), and had a disease duration 
of ≤ 1 year. 
 
Recruitment of interview participants and composition of focus groups 
Patients included in the CareRA trial before January 2012 could be invited by their 
rheumatologist for an individual interview if this could be scheduled within 4-6 months after 
treatment initiation. From the list of 46 eligible patients, participants were purposively 
sampled based on type of rheumatology practice and geographic region. Patients obliged or 
deciding to discontinue RA treatment were also considered. 
 
Twenty-six patients were interviewed at t1, and all of these were invited to participate in the 
subsequent focus groups, except one who withdrew trial consent. Seven interviewed 
participants declined to engage in a focus group because they either did not want to share 
their experiences, felt uncomfortable in a group or were afraid to face their peers. Four 
participants later declined their group participation because of scheduling conflicts. 
Eventually, three focus groups were held, with a total of 14 participants. A flow chart of 
participant recruitment is displayed in figure 1. Table 1 presents the well-balanced participant 
characteristics at both measurement points.  
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The Human Research Ethics Committee of the University Hospitals Leuven approved this 
study; participants provided written informed consent (23). 
 
Data collection 
Between April and August 2012, KE and SM conducted face-to-face, semi-structured 
individual interviews at the participants’ home or at the rheumatology clinic (their preference). 
The interview structure is presented in table 2. Interviews lasted about 45 minutes. 
 
In March 2013, KE conducted focus groups at non-clinical locations, with SM observing 
group interactions. After discussions with the patient researchers, we opted to use a modified 
nominal group technique to structure the focus groups and stimulate interactions (24). Focus 
groups consisted of three rounds (Table 2) and lasted about one hour. 
 
The interview guides were developed with the help of our patient researchers and contained 
open-ended and probing questions (Table 2). Based on the insights gained from the first 
interviews, we added three questions to the t1 interview guide to enrich data collection (25-
27). Interviews were audiotaped and transcribed verbatim. Observational field notes were 
documented for interviews and focus groups; these were related to setting, participants’ 
behavior, interaction between participants, and remarkable quotations. These notes were 
used as contextual information when analyzing and interpreting the data (20). Participants 
completed a pre-interview questionnaire documenting sociodemographic and clinical 
information. After the interviews, they self-reported their general health, level of pain, and 
fatigue during the past week on a visual analog scale (VAS) (Table 1). 
 
Data analysis 
Data analysis and collection were performed concurrently, with analysis beginning 
immediately after the first interview. Qualitative Analysis Guide of Leuven (QUAGOL) with 
the constant comparison method was used to analyze individual interviews and focus groups 
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(26). The two patient researchers were involved in the entire analysis process, helping the 
researchers to understand and explain the data. 
 
Interview transcripts were independently analyzed by two researchers (KE, SM) and the two 
patient researchers. They read each transcript several times to grasp its essentials. For each 
interview, fragments deemed relevant for answering the research question by each analyst 
were extracted and coded; similar codes were grouped and sorted into potential themes. 
Insights from new interviews were constantly used to further uncover and refine emerging 
themes and subthemes. Consensus on the individual coding was reached by the analysts, 
and this master list of codes was entered in NVivo 10® by the researchers. 
 
After the data were reviewed and coded, we adopted Saldaña’s guiding questions for 
analyzing longitudinal data (Table 3) (28). The meaning and phrasing of codes and themes 
were discussed in peer debriefings, which included input from patient researchers, 
rheumatologists, nurses, and clinical researchers. 
 
 
Findings 
At t1 and t2, participants’ views on preferred outcomes were related to four aspects inherent 
to the overarching outcome of a return to being normal: (1) aspects of disease control, (2) 
physical aspects, (3) aspects of participation, and (4) mental aspects (Figure 2). Table 4 
shows example quotes illustrating the findings. 
 
Return to being normal 
At t1, participants were generally set on returning to their normal life as soon as possible and 
this in its narrowest sense. They described a struggle to stay normal and hoped to re-
establish their former health, not constantly being aware that they have RA. At t2, participants 
were more subtle and nuanced in their normality expressions, and mentioned now 
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preferences like “remaining bodily well” and “controlling my RA”. Yet, they still preferred to 
have a life as normal as possible. Participants also referred to their ‘healthy’ peers, wanting 
to grow old in a comparable way. Normality was a personal construct, shared among all 
participants. 
 
Aspects of disease control 
Proof of disease control 
Particularly at t1, participants expressed the need for visual feedback about test results in 
order to objectify their disease evolution. When being ‘obliged’ to take more medication, they 
hoped that this would at least have a clear positive effect on their health. This proof of 
disease control provided reassurance. At t2, they still wanted such proof but less strongly.  
 
Prevention or stabilization of joint damage 
Participants mentioned joint damage more frequently at t1—especially those knowing 
someone with joint malformations—because they merely perceived it as a worst-case 
scenario of having ‘rheumatism’. At t2, participants’ initial fear of and focus on joint damage 
diminished.  
 
Less medication 
Less medication was a dominant outcome preference at t1, a time when most participants 
had just been prescribed a combination of disease-modifying antirheumatic drugs with a 
glucocorticoid-bridging scheme. A reduction in medication—inherent to the study protocol—
was viewed as health improvement proof. Participants feared for long-term adverse effects of 
medication and believed a reduction would limit these. They also struggled mentally with a 
sudden need for drugs after previously being ‘healthy’. They hoped to discontinue RA 
therapy, although this was considered unlikely. 
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At t2, taking medication was still viewed as unpleasant, but participants expressed less 
resistance and perceived it more as necessary for disease control, which they considered 
more important than having to take medication. However, less medication was still 
considered preferable because of side effect concerns.  
 
Physical aspects 
Relief of pain and other physical symptoms 
At t1 and t2, participants identified pain relief as a major outcome preference, surpassing their 
preference to be relieved of other physical symptoms, such as fatigue, swelling, and 
stiffness. Some preferred to be symptom-free, while others were satisfied with a lower level 
of symptoms. Participants were eager to start treatment, especially for pain. They preferred 
immediate pain relief and this was experienced as a reassuring and promising treatment 
start. 
 
At t2, pain relief, especially the ‘intolerable’ pain related to flares, remained a highly preferred 
outcome, despite perceived disease control. Participants feared their initial pain experience 
and remembered its impact on daily life. They identified pain as an outstanding symptom and 
focused less on other symptoms. Physical symptoms were regarded more as the inevitable 
consequences of RA, reflected in expressions like “a flare can occasionally be expected”. 
Relief of fatigue was not singled out anymore at t2, despite participants reporting comparable 
VAS fatigue levels at t1 and t2 (Table 1). 
 
Improved joint function and mobility 
Especially at t1, participants preferred to be able to do basic functions themselves again (e.g., 
opening cans, taking stairs), which were self-evident before. This preference underscored 
their diminished strength, grip, fine motor skills, and mobility, abilities that needed to be 
restored. 
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At t2, participants were more focused on social participation, in general, except in cases of 
perceived “setbacks”; then, they focused on regaining a basic level of physical functioning. 
 
Limited side effects 
At t1, participants’ preference to limit side effects of RA medication were a main concern, 
because these affected their sense of normality (e.g., weight gain created frustrations and 
shame; nausea limited social participation), or because of being biased against the 
prescribed medication. Furthermore, they feared but hoped not to compromise their long-
term health by taking such “strong” drugs. 
 
At t2, their initial fear decreased, and although side effects were still of concern, these were 
more accepted. New expressions, such as “no additional side effects” and “feeling more 
comfortable with side effects” emerged. Participants weighted to a higher extent the benefits 
of treatment against its side effects. Concerns about the long-term impact of medication, 
however, remained present. 
 
Improved sleep 
At t1 and t2, improved sleep was of concern to participants who experienced or feared a 
significant impact of pain on their sleep, which was specifically mentioned as a reason why 
pain relief remained a highly preferred outcome at t2. 
 
Aspects of participation 
Performing activities of daily living 
At t1, participants mainly focused on self-care and domestic activities. Their minds were fixed 
on doing everyday activities normally: autonomously, spontaneously, and at the same pace 
and ease as before. Loss of autonomy was a main cause of frustration, and extremely 
important for them to regain. 
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At t2, participants came more to terms with a shifted performance state, such as more readily 
accepting help and trying to pace their activities. Nevertheless, their goal remained to regain 
normal participation. 
 
Engaging in work and/or leisure  
At t1 and t2, participants expressed the importance of being active again, remaining involved 
in social activities and continuing hobbies. They feared being excluded from social activities, 
or being unable to engage fully. Employed work was especially important at t1, because they 
did not want to fail at their previously mastered tasks. Work became less important over time 
for those experiencing ongoing disease impact. 
 
Fulfilling family, social, and/or societal roles 
Participants expressed the need to fulfill their normal roles and activities again in the family 
and with friends. A key concern was whether they could keep up with relatives, friends, and 
colleagues. 
 
Family and social roles were discussed more at t2. In general, limited change in role 
preferences was expressed. For the youngest participant, her future role as a mother 
became more apparent because she experienced limited improvement.  
 
Vitality 
At t1, regaining vitality was a preferred outcome among those unable to participate in daily life 
as before. Participants talked about needing more physical energy and regaining the mental 
drive to start and pursue activities. Some mentioned vitality and fatigue together as being 
closely related. At t2, participants did not specifically discuss vitality. 
 
Mental aspects 
Emotional well-being 
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The RA diagnosis was shocking and led to uncertainty about what to expect from having 
‘rheumatism’. At t1, participants were still emotionally overwhelmed. Hope remained the 
strongest emotion, both for the present and future (e.g., hope that treatment would have 
lasting effect). At t1 and t2, the experience of pain persistency, disease progression and the 
need to adapt treatment (which was associated with a lack of improvement), led to doubts 
and additional mental distress. Regaining their emotional well-being was underscored more 
at t1 as being important for themselves and for reassuring their significant others. Other 
shared preferences were having happy relationships and understanding from family and 
friends. Generally, participants described a more significant psychological impact during the 
early phase and their disease-related emotions and cognitions changed later in the disease 
course. 
 
Self and identity 
Suddenly having to rely on others at a young age, failing at simple daily tasks, diminished 
family and social roles, and feeling like a burden to others affected participants’ self-esteem. 
They referred to their pre-RA identity, comparing it to their current one and longing to regain 
a normalized sense of self. 
 
Life enjoyment 
At t1, participants preferred to have more life enjoyment, which was altered by their current 
disease concerns. At t2, their mental outlook was more positive; they seemed to enjoy the 
daily things in life again, despite RA. 
 
Not feeling ill 
Particularly at t1, participants did not want to feel ill, especially when being confronted with 
physical symptoms, disabilities, and taking medication. They did not want to be patronized or 
treated like a sick person. For those who felt well again, taking medication became a daily 
confrontation with RA. 
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Discussion 
We prospectively unraveled, for the first time, the health and treatment outcome preferences 
of patients with ERA. Our study showed shifting outcome preferences in the early stages 
after RA diagnosis and treatment initiation, with “normality” as overarching theme. 
 
As with previous qualitative studies on the patient perspective (10-13, 29-32), normality was 
a prominent theme in our study. For example, Sanderson et al. distinguished six normality 
typologies in RA (33). However, despite the obvious similarities, these findings in RA and 
other chronic conditions involved patients in a different context, making them challenging to 
compare with our findings derived prospectively in patients at an early disease stage. 
 
Our patients with ERA initially conceptualized this normality as regaining the health and life 
they had before RA, as soon as possible. Thus, they preferred a rapid improvement 
(especially for pain). This gave them hope and helped them to deal with fear and uncertainty. 
These are meaningful discoveries, as new patients gradually shape their understanding and 
attitude toward RA, but initially lack experience and illness identity. Regarding adjustment to 
RA, the role of illness perceptions has been described previously (34), whereas patients who 
received a quick diagnosis and effective medical treatment perceived their life to be 
unaffected by RA (35). This is consistent with Kristiansen et al.’s findings that patients in 
early clinical remission continue to experience living a normal life (36). These findings, 
together with our data support the view that, aside from its importance when targeting 
classical disease outcomes in ERA, time could also be crucial from the patient perspective. 
Perhaps, the present findings point to a new opportunity for prevention. Health-care 
professionals should then endeavor to meet patients’ initial normality construct in all its 
aspects, to help them adjust to RA in a healthy way, and to intervene before “illness-as-
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burden beliefs” get rooted (37, 38). Nurses can be seen as pivotal in providing such 
necessary psychosocial care (39, 40). 
 
We observed subtle changes over time in how normality was shaped. Participants developed 
a more realistic and coherent view (e.g., symptom normalization, medication as being 
necessary at the moment) having passed that particular acute disease phase, which fits with 
theoretical models on chronic illness management (14, 37). This altered view made their 
initial pre-RA normality shift to a normality that was not completely as going back to their pre-
disease life. This was especially the case for those who perceived an unsatisfactory 
treatment response. Nevertheless, at the second time point, participants remained close to 
their preferred pre-RA normality like recently after diagnosis. The notion of normality in the 
early disease stage should be further developed and studied in other settings and cultures. 
 
Over time, participants did not report new preferred outcomes. Pain relief remained a 
predominant outcome preference, as in previous RA research (41, 42). Unexpectedly, fatigue 
relief was rarely mentioned later in the ERA disease course, even though it has been 
proposed as a patient-preferred outcome in late RA (43). The apparent discrepancy between 
relatively stable reporting of fatigue by VAS over time and the decreasing importance 
reflected in the focus groups needs more study. Other outcomes that were less or no more 
mentioned over time were related to proof of disease control, joint damage prevention, sleep 
quality, vitality, self and identity, life enjoyment, and not feeling ill. Moreover, changes in 
participants’ perspective started to emerge with a focus beyond treatment issues. These 
dynamics points to the continued need for longitudinal studies to understand patient 
expectations in different stages of their disease, to successfully adapt RA care processes 
(14). 
 
Our findings provide a framework for promoting effective communication between health-
care professionals and new patients based on shared goals and understanding (15, 44, 45). 
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Patient-centered information exchange is key in constructing such partnership (46). In ERA, 
health-care professionals should include normality in their conversations; explore what this 
normality means to each patient and discuss the management of potential threats to it. 
Moreover, this study learned us that newly diagnosed patients with RA prefer a rapid and 
prolonged treatment response, preferably without side effects and without chronic medication 
use. These findings emphasize the importance of addressing an immediate pain-reducing 
effect, coping with pain and side effects, potential side effects, and prospects of drug-free 
remission and medication tapering. Patient empowerment and self-advocacy could then be 
established early in the chronic disease course (47). 
 
Health-care professionals also need to remember that patient-preferred outcomes in ERA 
can be dynamic and need repeated evaluation. For example, aspects of participation should 
be discussed more into depth later on, and the altered focus on joint damage prevention 
underscores the need for ongoing patient education on RA treatment targets. 
 
Employing individual interviews and focus groups at different times produced methodological 
challenges. Firstly, not all participants of the individual interviews (t1) were willing to take part 
in the focus groups (t2). Using repeated interviews might have increased participation. We 
invited participants for the future focus group immediately after the interview; perhaps, they 
would have reacted more positively if invited later. Nevertheless, the fact that some 
participants felt uncomfortable to participate in a group setting supports our choice to conduct 
individual interviews at t1 to respect their adjusting to the recent diagnosis. Secondly, we 
could have addressed dropout at t2 by inviting those who declined to participate in focus 
groups for an interview, circumventing possible selection bias in the focus groups. However, 
characteristics such as age, gender, and treatment progress were comparable between 
participants and nonparticipants. Thirdly, the different interview methods could have 
influenced change over time. Furthermore, the outcome prioritizing in the focus groups 
enabled us to elicit the breath of views, but ultimate priority setting needs further study using 
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appropriate instruments, like questionnaires (48). Lastly, participants were not interviewed at 
treatment initiation for practical reasons, and because of their immature disease perspective 
early on. 
 
The present study is innovative in two ways. Firstly, it was explicitly oriented toward ERA, a 
disease period with specific dynamics. Secondly, interviewing the same participants at 
multiple times allowed us to scrutinize patient-preferred outcomes at a disease stage when 
opinions could change. Trustworthiness of our findings was increased in five ways. Firstly, 
our research team included two trained patient researchers, who provided unique insight on 
methodological reflection, interview guide development, data analysis, and manuscript 
revision. Secondly, interdisciplinary team discussions gave us a broad view of the data. 
Thirdly, inductive analysis ensured that outcomes emerged from participants’ stories. 
Fourthly, trial participants shared characteristics with a typical ERA population and were 
treated using the same protocol, supporting data transferability. Finally, purposive sampling 
aided diversified information gathering. 
 
We conclude that the core patient-preferred outcome of patients with ERA is the urge to 
return to a normal life. Over the ERA course, this search for normality involved different 
levels: aspects of disease control, physical and mental aspects, and aspects of participation. 
There were nuanced changes, but with pain relief remaining prominent. Our study provides 
evidence crucial for designing more targeted and holistic therapeutic interventions in ERA. 
Additional prospective quantitative research is needed to fully understand the potential of 
including patient-preferred outcomes in ERA management. 
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*Patients included in the CareRA trial were eligible for an individual interview if this could be scheduled 
within four to six months after start of the initial treatment (t1). t2: at least one year after start of the 
initial treatment for early rheumatoid arthritis. 
Figure 1. Flow chart of participant recruitment for individual interviews and focus groups  
Patients considered ineligible by rheumatologist: N=5  
 Non-native Dutch speaker: N=1 
 Loss to follow-up: N=2 
 Unknown reason: N=2 
Patients excluded because rheumatologist declined to participate: N=3  
Patients excluded because rheumatologist invited them too late: N=5 
Patients declining to participate in an individual interview: N=2 
Patients not invited after consideration of data richness: N=5 
Participants interviewed individually at t1: N=26 
(Treating rheumatologists: n=11) 
Participants declining to participate in a focus group: N=7  
Participants reconsidering their participation because of scheduling conflicts: N=4 
 Distance to focus group too far: N= 2 
Personal reasons: N=2 
Participants interviewed in a focus group at t2: N=14 
(Treating rheumatologists: n=6) 
Participants interviewed individually at t1 and invited to participate in a focus group at t2: 
N= 25 
(Treating rheumatologists: n=11) 
Participant excluded because treatment discontinued: N=1 
Patients enrolled in CareRA trial on January 1, 2012: N=262 
(Treating rheumatologists: n=25) 
Patients eligible* for individual interview at t1: N=46 
(Treating rheumatologists: n=20) 
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Figure 2. Overview of patient-preferred outcomes in early rheumatoid arthritis 
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Table 1. Participant demographic, clinical, and self-reported health characteristics grouped 
by interview time (t1 or t2) 
Participant characteristics Individual 
interviews at 
t1 (n=26) 
Focus groups 
at t2 (n=14
*) 
Median (range) age in years  55 (22-68) 57 (23-66) 
Median (range) general health scores 
(VAS)† 
24 (0-64) 38 (0-80) 
Median (range) pain scores (VAS)† 22 (0-65) 37 (0-80) 
Median (range) fatigue scores (VAS)† 29 (0-64) 37 (0-80) 
Women, n (%) 18 (69) 9 (64) 
Site of recruitment, n (%)   
 Private practice 9 (36) 3 (21) 
 General hospital 8 (28) 5 (36) 
 Academic hospital 9 (36) 6 (43) 
Geographic location of site, n (%)   
  Antwerp 1 (4) 0 (0) 
  Limburg 9 (35) 4 (29) 
 
Flemish Brabant 
East Flanders 
West Flanders 
12 (45) 
1 (4) 
3 (12) 
8 (57) 
1 (7) 
1 (7) 
Treatment progress, n (%) 
 
Patient decided to discontinue 
treatment 
1 (4) - 
 Treatment failures‡ in the first year 
4 (15) 3 (21) 
 Treatment failures‡ after one year 
1 (4) 1 (7) 
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 Treatment responders 20 (77) 10 (72) 
*Out of the initial 26 participants interviewed at t1, 14 agreed to participate in a 
focus group conducted at t2. 
†
Position marked on a 100-mm visual analog scale (VAS). 
‡
A treatment failure in the CareRA trial was defined as an efficacy failure when 
failing to reach low disease activity even after two predefined treatment 
adjustments or as a safety failure in case of persistent toxicity.  
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Table 2. Main interview questions and procedures for the individual interviews and focus 
groups 
Individual 
interviews at t1 
Interview questions and procedures 
 Preparatory phase (5 to 10 minutes) 
 To set the scene for the interview, participants were asked to 
write down as many keywords describing: 
- the impact of RA on their life 
- which outcomes of their illness and treatment they 
considered most important. 
 Start of the interview 
 The interviews began by discussing participants’ written answers 
to those two questions. Participants were asked to elaborate on 
their keywords. 
- Can you tell me how RA affects your daily life? 
- Which outcomes of your illness and antirheumatic 
treatment are important to you at this moment? 
 Proceeding of the interview 
 The order of the other interview questions was determined by 
the participants’ answers during the interview: 
- How has the treatment been working for you so far? 
- How do you decide whether or not your treatment is 
working? 
- What made you decide to start treatment? 
- What were your expectations of your antirheumatic 
treatment at the start of treatment? 
- To what extent do the expectations you had at the start 
Page 27 of 35
John Wiley & Sons, Inc.
Arthritis Care & Research
This article is protected by copyright. All rights reserved.
28 
 
of your treatment match your current expectations? 
 *Three questions were added after the first interviews:  
Other patients talked about taking less medication*, returning to 
a normal life*, feeling better*. Is this something you recognize? 
What do you feel about that? 
 Probing questions: Could you tell me more about that? Could 
you give an example? 
 End of the individual interview: Is there anything else you 
would like to add? 
Focus groups 
at t2 
 
 Round 1: Preparatory phase (5 to 10 minutes) 
 The moderator introduced the phenomenon of interest, after 
which each group member was asked to independently prepare 
answers to the question below by writing down as many 
keywords as possible. Each answer was written on a separate 
Post-it®. 
- Which outcomes of your illness and antirheumatic 
treatment are important to you at this moment? 
Next, participants were asked to try to order their Post-its® on a 
vertical scale, from most important (top) to least important 
(bottom). 
Participants were simultaneously asked to think about the 
following questions: 
- What important treatment results have already been 
achieved? 
- At present, is there anything you would like to change or 
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improve regarding your disease or treatment? 
 Round 2-step 1: Round-robin listing 
 All group members were asked to reveal and clarify, one by one, 
their personally preferred outcomes in order of importance. 
Meanwhile, the observer wrote these outcomes on a flipchart in 
front of the group. 
- Who would like to share your personally valued 
outcomes with the group, in order of importance? 
- Could you please clarify why these outcomes of your 
disease and antirheumatic treatment are important to 
you? 
- Why did you designate that specific outcome to be the 
most important? 
- Is there anything else you would like to add? 
 Round 2-step 2: Developing a group list of patient-preferred 
outcomes 
 The group was asked to generate a consensus list by reviewing 
and merging all recorded outcomes and agreeing on the name 
and properties of each outcome on the list. 
- Could any of the individual expectations be grouped? 
- Who would like to suggest a name and meaning for this 
outcome? 
- Do you think all the important outcomes are mentioned 
on the group list? Is there anything else you would like to 
add? 
 Round 2-step 3: Eliciting personal preferred outcomes 
 Starting from the consensus list of patient-preferred outcomes 
Page 29 of 35
John Wiley & Sons, Inc.
Arthritis Care & Research
This article is protected by copyright. All rights reserved.
30 
 
that resulted in step 2, each group member was asked to 
independently try to select his or her five top outcomes from this 
list, using the Post-it® ordering scheme. 
 Round 2-step 4: Eliciting preferred outcomes in the actual 
stage of RA 
 The group was then asked to discuss a collective top 5 
outcomes and to consider influencing factors. 
- Looking at the group list, what outcome would you order 
as most important? 
- What outcome would you order secondZfifth? 
- Can you tell us why this outcome is either important to 
you or not? 
 End of round 2: That is it for the second round. Is there 
anything else to add? 
 Round 3: Exploring the view of participants on the evolution 
of their patient-preferred outcomes over the past year 
 The focus groups ended by exploring the participants’ views on 
potential changes in personally preferred outcomes over time: 
During the individual interview of last year, you were asked for 
your preferred illness and treatment outcomes. In the meantime, 
you have gained more experience with your disease and 
treatment and the critical disease stage has passed. 
- Do you feel that other results are now more important to 
you than the ones you identified at the start or during 
your interview last year? 
- Could you explain why this has or has not changed? 
- Are there outcomes that are now more, less or no longer 
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important to you? 
- Why do you think that these are now more or less 
important than a year ago, or are no longer important? 
What may have caused this change in importance? 
- Do you have an example of an outcome that has 
changed in importance compared to that outcome in the 
early disease stage? Why do you think this has 
changed? Could you clarify this in more detail? 
- In general you mention (more or less) similar/different 
outcomes of importance compared to last year (in the 
early disease stage). What is your opinion on this 
observation? 
 End of round 3: This is the end of the third round. Is there 
anything else to add? 
 Probing questions: Is this outcome also important or not 
important to other group members? Are there any suggestions 
from other group members? Is there anyone who has a different 
opinion on the matter? Is it difficult for you to share your opinion 
on this? Does everyone agree? Who agrees or disagrees and 
why? Who would like to add something? 
 End of the focus group 
- What is your general conclusion about today’s focus 
group on preferred and important outcomes of disease 
and treatment in the actual disease stage? 
- To summarize, you talked about [Z]. 
- Do you agree with this summary of today’s focus group? 
t1: Four to six months after start of the initial treatment for early rheumatoid arthritis. 
t2: At least one year after start of the initial treatment for early rheumatoid arthritis.  
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Table 3. Example of guiding questions based on Saldaña’s method for analyzing longitudinal 
data 
Set of questions Example questions 
Framing questions What contextual factors appear to influence 
and affect change in participants’ preferred 
outcomes through time? 
Descriptive questions What increases or emerges through time? 
Analytic and interpretive questions Which changes interrelated through time? 
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Table 4. Quotes of participants that illustrate the outcomes preferred by patients with early 
rheumatoid arthritis 
Return to being normal 
“No more pain, just functioning normally again. Like everybody else, just being a 
healthy person.” (t1, woman, 29 years old) 
“Yet, I think the expectation is ‘being able to do what you could do before’. 
(t2, man, 60 years old)  
Yeah, that you are still capable of doing things like you were used to.” 
(t2, man, 57 years old) 
Aspects of disease control 
Proof of disease control “If I can see it in my blood that my inflammation goes down 
well yesZ there is proof.” (t1, woman, 40 years old ) 
Prevention or stabilization 
of joint damage 
“My grandmother also had RA, but her fingers got deformed, 
so I thought the faster I could start treatment, the better." (t1, 
woman, 29 years old) 
Less medication “Medication will always be there. We can’t go on without 
those meds.” (t2, man, 51 years old) 
Physical aspects 
Relief of pain and other 
physical symptoms 
“Yes in the first instance the pain of course and afterwards the 
rest will follow automatically I think.” (t1, woman, 31 years old) 
 “I am very happy that the pain has gone. That rigid feeling 
and so onZwe have to accept it I guess, if that’s all.” (t2, 
woman, 59 years old) 
 “Yeah, being tired, I take it into account, so I can go to sleep.” 
(t2, man, 51 years old) “Indeed, you can solve it by going to 
bed earlier.” (t2, woman, 54 years old) 
Improved joint function and “Walking, taking stairs, opening a bottle, tying your 
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mobility shoelacesZthese are things every normal person is able to 
do, no?” (t2, man, 57 years old) 
Limited side effects “I do not expect that all these side effects will disappear, but 
there are a number of them that are bothering me and I hope 
those improve.” (t2, woman, 60 years old) 
Improved sleep “If you can’t sleep no more [because of the pain], then you are 
prepared to take the medication again.” (t2, woman, 56 years 
old) 
Aspects of participation 
Performing activities of 
daily living 
“I do my work independently. Washing, ironing, I do it all back 
again myself.” (t1, woman, 65 years old) 
 “To keep functioning in daily activities, I do find it essential.” 
(t2, woman, 54 years old) 
Engaging in work and/or 
leisure 
“If you like to work in the garden, you can do that again. If you 
like to bike, you can bike again and if you like to jog, you can 
jog again. Things like that.” (t2, man, 57 years old) 
 “I love doing my job. The rheumatologist said at the start of 
treatment: ‘We are going to make sure that you can keep 
doing your job.’” (t1, woman, 31 years old) 
Fulfilling family, social, 
and/or societal roles 
“Being able to keep up with the others. Being an ordinary 
grandmother.” (t2, woman, 63 years old ) 
Vitality “That you can get up in the morning and say, ‘I’m going to do 
this and that’, and then really being able to realize these plans 
and afterwards being energetic enough to do other things.” (t1, 
woman, 29 years old) 
Mental aspects 
Emotional well-being “Yes, if you are always crying from pain, or if you are so 
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depressed or not being able to sleep and always cryingZ 
Now I’m able to laugh and to sing again, and when people are 
asking me, ‘How are you?’, you can say, ‘I’m fine!’.” (t1, 
woman, 55 years old) 
 “Calmer, being more at ease. How do I have to explain it. In 
the beginning you want to be cured, you want it [the disease] 
to be gone, to take your medication and it is gone. Now you 
know that it’s not going to pass.” (t2, man, 51 years old) 
Self and identity “Yeah, you knowZfear that you do not want to give in when 
being away in the group. It may sound dramatic but mentally it 
wears you down. I’m feeling like a burden to others.” (t1, 
woman, 59 years old) 
 “And when I had to drag myself on and on, I thought to myself 
‘that’s not me’.” (t1, woman, 49 years old) 
Life enjoyment “Just want to enjoy things again, can I say that? I don’t want 
to think constantly about the pain, so I can walk again with my 
boyfriend and my dog, so I can go for a drink again with 
friends or have a nice cozy dinner. Yeah those sorts of 
things.” (t1, woman, 31 years old) 
Not feeling ill “I am 40 years old and I may not feel like this [ill]. I should be 
able to walk normally and not have pain in my foot or knee. 
Just not thinking that there is something wrong.” (t1, woman, 
40 years old) 
Changes over time: “I think a part [of the outcomes] that were mentioned as a priority last 
year, are possibly already fulfilled by the tapering of the medication etc., and your reaction is 
already better to the medication, that’s why you feel better. So this part is already achieved, 
and now you can focus more on the functioning.” (t2, woman, 54 years old) 
Page 35 of 35
John Wiley & Sons, Inc.
Arthritis Care & Research
This article is protected by copyright. All rights reserved.
